LianMedical Completes Merger with LianBio and Launches New Chapter as Medical Device Innovation Company
LianMedical, formerly known as LianBio, has announced the successful completion of its previously disclosed corporate merger, marking a significant milestone in the company’s strategic transformation from a biotechnology-focused organization into a medical device company dedicated to expanding access to innovative healthcare technologies across China and the Asia-Pacific region.
The transaction concludes the merger between LianBio and LianMedical, with LianBio continuing as the surviving legal entity following completion of the merger. As part of the restructuring, the surviving company has officially changed its corporate name from LianBio to LianMedical, reflecting its renewed strategic focus on the development and commercialization of advanced medical technologies.
The merger represents more than a corporate name change. It signals the company’s long-term commitment to building a diversified medical technology platform designed to introduce cutting-edge global medical devices into rapidly growing healthcare markets where demand for innovative treatment solutions continues to increase.
Strategic Transformation into a Medical Technology Company
Over the past several years, healthcare markets across Asia have experienced growing demand for innovative medical devices capable of improving patient outcomes while addressing significant unmet clinical needs. As healthcare systems continue to modernize, companies that can successfully introduce advanced technologies into these markets are positioned to play an increasingly important role in patient care.
LianMedical’s newly established strategy centers on identifying best-in-class medical technologies developed around the world and accelerating their availability throughout China and other Asia-Pacific countries.
Headquartered in Shanghai, the company intends to serve as a bridge between global medical device innovators and regional healthcare providers by combining licensing, product development, regulatory expertise, and commercialization capabilities.
Rather than focusing on a single therapeutic area, LianMedical plans to build a diversified portfolio of innovative medical technologies while prioritizing disease areas where existing treatment options remain limited.
Expanding Access to Innovative Medical Devices
The company’s primary objective is to improve patient access to advanced healthcare technologies that have already demonstrated clinical value internationally but remain unavailable or underutilized in Asian markets.
Many breakthrough medical devices are initially developed and commercialized in North America or Europe before expanding globally. However, regulatory differences, reimbursement systems, and commercialization challenges can delay patient access in other regions.
LianMedical aims to reduce these barriers by partnering with global innovators and introducing proven technologies into China and neighboring markets through localized development and commercialization strategies.
The company believes this approach will help accelerate the adoption of advanced medical devices while improving treatment options for physicians and patients across the region.
Focus on High-Unmet Clinical Needs
An important component of LianMedical’s business strategy is concentrating on therapeutic areas where significant unmet medical needs remain.
Rather than pursuing broad expansion across every medical specialty, the company plans to prioritize technologies capable of addressing diseases with limited treatment alternatives or growing healthcare burdens.
Its portfolio strategy is designed to identify products that offer meaningful clinical differentiation while improving patient outcomes.
According to the company, this disciplined investment approach allows resources to be allocated toward technologies with the greatest potential clinical and commercial impact.
By combining innovation with careful portfolio management, LianMedical hopes to establish a sustainable growth platform capable of delivering long-term value to healthcare providers, patients, and shareholders.
Initial Commercial Progress Already Underway
LianMedical noted that it has already begun generating commercial revenue through its initial product activities.
Although the company did not disclose detailed financial figures or specific product names, the announcement indicates that commercialization efforts have moved beyond the development stage.
Generating early revenue provides an important foundation for future expansion as the company continues introducing additional products into its portfolio.
Commercial traction also demonstrates the company’s ability to navigate regulatory approval processes, establish distribution networks, and engage healthcare providers within its target markets.
These early achievements are expected to support broader commercialization initiatives over the coming years.
Leadership Highlights Long-Term Vision
Commenting on the completion of the merger, Luxin Wang, Chief Executive Officer of LianMedical, described the transaction as an important milestone in the company’s ongoing evolution.
According to Wang, the merger establishes a stronger platform for accelerating patient access to differentiated medical technologies throughout China and other Asian markets.
He explained that the company’s strategy focuses on building a disciplined, portfolio-oriented medical technology business capable of identifying innovative healthcare solutions and bringing them to patients more efficiently.
Wang also noted that LianMedical intends to begin executing this strategy with an initial emphasis on heart failure, an area where substantial unmet clinical need continues to exist despite advances in medical treatment.
The company believes this focused approach will enable it to expand methodically while maintaining strong scientific and commercial discipline.
Heart Failure Becomes an Early Strategic Priority
Heart failure represents one of the world’s leading causes of hospitalization and mortality, affecting millions of individuals globally.
The condition places enormous pressure on healthcare systems due to frequent hospital admissions, long-term treatment requirements, and substantial healthcare costs.
Although pharmaceutical therapies have improved patient outcomes over recent decades, many individuals continue to experience progressive disease that requires additional treatment options, including innovative medical devices.
LianMedical has identified heart failure as one of its first strategic focus areas because of the growing need for advanced technologies capable of improving cardiac function, reducing hospitalization rates, and enhancing quality of life.
By concentrating initially on cardiovascular innovation, the company hopes to establish a strong foundation before expanding into additional therapeutic categories.
Details of the Merger Transaction
The merger was completed in accordance with the previously approved Plan of Merger, which received shareholder approval before the transaction became effective.
Under the terms of the agreement, the merging entity was combined into LianBio, with LianBio surviving as the legal corporate entity before subsequently changing its name to LianMedical.
As part of the transaction, shareholders of the merging company received newly issued shares in the surviving company based on a predetermined exchange ratio.
Specifically, every ordinary share of the merging company outstanding immediately before completion of the merger was cancelled in exchange for 68.3775 ordinary shares of the surviving company.
Any resulting fractional shares were rounded up to the nearest whole ordinary share.
Meanwhile, existing LianBio shareholders retained ownership of their ordinary shares, which continued as validly issued, fully paid, and non-assessable ordinary shares of the renamed company, subject to the treatment of dissenting shareholders under Cayman Islands law.
This structure ensured continuity for existing shareholders while facilitating the integration of the two organizations into a single corporate entity.
Experienced Legal Advisors Supported the Transaction
Both companies retained internationally recognized legal advisors throughout the merger process.
The merging company received legal counsel from:
- Ropes & Gray LLP on United States legal matters
- Travers Thorp Alberga on Cayman Islands legal matters
LianBio was advised by:
- Womble Bond Dickinson (US) LLP on United States legal matters
- Mourant Ozannes (Cayman) LLP on Cayman Islands legal matters
The participation of experienced cross-border legal advisors helped ensure that the transaction complied with applicable corporate, securities, and Cayman Islands legal requirements.
Continued Trading of American Depositary Shares
Following completion of the merger and corporate name change, the company’s American Depositary Shares (ADSs) will continue trading on the OTC Pink Market under the ticker symbol “LIANY.”
Maintaining the existing trading symbol provides continuity for investors while the company transitions to its new corporate identity.
The continued public listing also enables the company to maintain access to U.S. capital markets as it pursues future growth opportunities.
Positioning for Future Growth
The completion of the merger marks the beginning of a new phase in the company’s development. By rebranding as LianMedical and adopting a focused medical technology strategy, the organization aims to strengthen its role as a partner for global healthcare innovators seeking to expand into Asia-Pacific markets.
Its emphasis on identifying differentiated medical devices, addressing significant unmet clinical needs, and accelerating commercialization reflects broader trends shaping the medical technology industry, particularly in rapidly growing healthcare markets such as China.
With early commercial revenue already being generated, an initial focus on heart failure technologies, and a portfolio-driven investment strategy, LianMedical believes it is well positioned to expand its presence across the region while improving patient access to innovative healthcare solutions. As the company continues building partnerships and introducing new medical technologies, it aims to establish itself as a leading medtech platform supporting the delivery of world-class medical innovation throughout China and the broader Asia-Pacific region.
About the Company
The Company is a medical device company with the mission to enhance patient access to world-class innovations. The Company is dedicated to advancing patient care through cutting-edge products and technologies, with a focus on bringing innovative medical technologies to China and other Asia Pacific markets.